Excess Cardiometabolic Risk in Children and Adolescents Initiating Antipsychotic Treatment Compared to Young Adults: Results from a Nationwide Cohort Study

Overview

Journal World Psychiatry

Date 2025 Jan 15

PMID 39810688

Authors

Mikkel Hojlund

Rikke Wesselhoeft

Michella Heinrichsen

Anne Katrine Pagsberg

Christoph U Correll

Hans-Christoph Steinhausen

Affiliations

Soon will be listed here.

Abstract

Antipsychotic treatment is associated with cardiometabolic risks that may be especially detrimental to children and adolescents. In this Danish population-based cohort study, we included individuals with psychiatric diagnoses who initiated antipsychotics in 2000-2021 at age 6-31 years. We assessed the risk of cardiometabolic adverse events up to 10 years following incident exposure to antipsychotics, compared to age- and sex-matched unexposed individuals with psychiatric diagnoses. Cox regression models were used to calculate hazard ratios (HRs) after adjustment using high-dimensional propensity scores, including age, sex, calendar time, hospital diagnoses, and prescription drug use. HRs were compared between incident exposure in youths (6-17 years) and young adults (18-31 years), and between incident exposure in children (6-11 years) and adolescents (12-17 years). The total cohort consisted of 335,093 individuals, including 36,092 subjects exposed to antipsychotics (children and adolescents: 8,547, mean follow-up: 6.8±3.2 years; young adults: 27,545, mean follow-up: 6.5±3.4 years) and 299,001 age-, sex- and calendar-matched unexposed subjects. The incidence rate of cardiometabolic events was higher for young adults initiating antipsychotics than for children and adolescents (23.2 vs. 14.1 events/1,000 person-years). However, the adjusted excess risk of cardiometabolic events was significantly higher in exposed compared to unexposed children and adolescents (HR=1.87, 95% CI: 1.71-2.05) than in exposed compared to unexposed young adults (HR=1.46, 95% CI: 1.40-1.51) (p<0.001). The excess risk of cardiometabolic events was even higher when antipsychotic treatment was initiated before age 12 years (HR=2.44; 95% CI: 1.99-2.98) than at age 12-17 years (HR=1.69, 95% CI: 1.52-1.87) (p=0.012). Concerning specific cardiometabolic outcomes, there was an effect of age at antipsychotic initiation on the risks of metabolic syndrome (p=0.011) and obesity (p<0.001), that were higher among children and adolescents than young adults. Thus, initiation of antipsychotic treatment before age 18 years is associated with an excess risk of cardiometabolic events compared to age- and sex-matched youths with psychiatric disorders but unexposed to antipsychotics. The excess cardiometabolic risk is significantly higher than that of individuals who start antipsychotic treatment in early adulthood, and significantly higher for treatment onset in childhood compared to adolescence. On the basis of these findings, recommendations are provided about the use of antipsychotics in children and adolescents.

References

Branford D, Webster A, Gill D, Randon T, Peebles K . Challenging use of psychotropic medication in young people. Drug Ther Bull. 2024; 62(8):114. DOI: 10.1136/dtb.2024.000022. View

Maayan L, Correll C . Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol. 2011; 21(6):517-35. DOI: 10.1089/cap.2011.0015. View

Singappuli P, Sonuga-Barke E, Kyriakopoulos M . Antipsychotic long-term treatment in children and young people: a systematic review and meta-analysis of efficacy and tolerability across mental health and neurodevelopmental conditions. CNS Spectr. 2021; 27(5):570-587. DOI: 10.1017/S1092852921000523. View

Nakane S, Tanaka-Mizuno S, Nishiyama C, Kochi K, Yamamoto-Sasaki M, Takeuchi M . Trends in Prescribing Antipsychotics for Children and Adolescents in Japan: A Descriptive Epidemiological Study Using a Large-Scale Pharmacy Dataset. Child Psychiatry Hum Dev. 2022; 54(5):1250-1257. DOI: 10.1007/s10578-022-01330-x. View

Helweg-Larsen K . The Danish Register of Causes of Death. Scand J Public Health. 2011; 39(7 Suppl):26-9. DOI: 10.1177/1403494811399958. View

Olfson M, Blanco C, Liu S, Wang S, Correll C . National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry. 2012; 69(12):1247-56. DOI: 10.1001/archgenpsychiatry.2012.647. View

Galling B, Roldan A, Nielsen R, Nielsen J, Gerhard T, Carbon M . Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2016; 73(3):247-59. DOI: 10.1001/jamapsychiatry.2015.2923. View

Nicol G, Campagna E, Garfield L, Newcomer J, Parks J, Morrato E . The Role of Clinical Setting and Management Approach in Metabolic Testing Among Youths and Adults Treated With Antipsychotics. Psychiatr Serv. 2015; 67(1):128-32. PMC: 4701636. DOI: 10.1176/appi.ps.201400428. View

Kakko K, Keskinen P, Pihlakoski L, Salmelin R, Puura K . In search of measures to improve the detection of increased cardiometabolic risk in children using second-generation antipsychotic medications. Nord J Psychiatry. 2021; 76(4):316-322. DOI: 10.1080/08039488.2021.1968489. View

10.

Correll C, Penzner J, Parikh U, Mughal T, Javed T, Carbon M . Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am. 2005; 15(1):177-206. DOI: 10.1016/j.chc.2005.08.007. View

11.

Firth J, Siddiqi N, Koyanagi A, Siskind D, Rosenbaum S, Galletly C . The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry. 2019; 6(8):675-712. DOI: 10.1016/S2215-0366(19)30132-4. View

12.

Tirosh A, Shai I, Afek A, Dubnov-Raz G, Ayalon N, Gordon B . Adolescent BMI trajectory and risk of diabetes versus coronary disease. N Engl J Med. 2011; 364(14):1315-25. PMC: 4939259. DOI: 10.1056/NEJMoa1006992. View

13.

Correll C, Cortese S, Croatto G, Monaco F, Krinitski D, Arrondo G . Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review. World Psychiatry. 2021; 20(2):244-275. PMC: 8129843. DOI: 10.1002/wps.20881. View

14.

De Hert M, Detraux J, van Winkel R, Yu W, Correll C . Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011; 8(2):114-26. DOI: 10.1038/nrendo.2011.156. View

15.

DelBello M, Correll C . Primum non nocere: balancing the risks and benefits of prescribing psychotropic medications for youth with bipolar disorder. Bipolar Disord. 2010; 12(2):113-5. DOI: 10.1111/j.1399-5618.2010.00796.x. View

16.

Correll C, Sikich L, Reeves G, Johnson J, Keeton C, Spanos M . Metformin add-on vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial. World Psychiatry. 2020; 19(1):69-80. PMC: 6953545. DOI: 10.1002/wps.20714. View

17.

Have M, Tuithof M, van Dorsselaer S, Schouten F, Luik A, de Graaf R . Prevalence and trends of common mental disorders from 2007-2009 to 2019-2022: results from the Netherlands Mental Health Survey and Incidence Studies (NEMESIS), including comparison of prevalence rates before vs. during the COVID-19 pandemic. World Psychiatry. 2023; 22(2):275-285. PMC: 10168151. DOI: 10.1002/wps.21087. View

18.

Ho J, Panagiotopoulos C, McCrindle B, Grisaru S, Pringsheim T . Management recommendations for metabolic complications associated with second-generation antipsychotic use in children and youth. Paediatr Child Health. 2012; 16(9):575-80. PMC: 3223901. View

19.

Correll C, Sheridan E, DelBello M . Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord. 2010; 12(2):116-41. DOI: 10.1111/j.1399-5618.2010.00798.x. View

20.

Correll C, Gerhard T, Olfson M . Prescribing of psychotropic medications to children and adolescents: quo vadis?. World Psychiatry. 2013; 12(2):127-8. PMC: 3683259. DOI: 10.1002/wps.20031. View